Potential Benefits of Statin Therapy in Reducing Osteoarthritis Risk: A Mendelian Randomization Study
Authors' conclusion
This MR study provides compelling evidence that statin treatment may be a protective factor for OA.
Study context
- Population
- GWAS summary data: statins from UK Biobank and FinnGen; Osteoarthritis (OA) from UK Biobank and arcOGEN
- Comparison
- Genetically proxied statin use vs no statin use
- Outcome
- OA risk (knee and hip OA)
Methodological detailstwo-sample Mendelian randomization (MR), inverse-variance weighted (IVW), MR-Egger, weighted median and weighted mode as supplementary analyses, sensitivity analyses: MR-Egger regression, Cochran's Q test, MR-PRESSO, summary data-based MR (SMR) for Hydroxymethylglutaryl-coenzyme A reductase (HMGCR) expression
- Two-sample MR
- Inverse-variance weighted (IVW)
- MR-Egger, weighted median and weighted mode as supplementary analyses
- Sensitivity analyses: MR-Egger regression, Cochran's Q test, MR-PRESSO
- Summary data-based MR (SMR) for HMGCR expression
Main finding
As reported in the abstract
- Atorvastatin on hip OA (IVW β)
- −2.989, P = 0.003
- Rosuvastatin on hip OA (IVW β)
- −14.141, P = 0.006
- Atorvastatin and knee OA (meta-analysis OR)
- 0.15; P = 0.004
- Simvastatin on knee OA (IVW β)
- −1.056, P = 0.004
- Simvastatin on hip OA (IVW β)
- −1.405, P = 0.001
- Statin medication on hip OA (IVW β)
- −0.054, P = 0.013
Further findings
HMGCR expression and OA risk (SMR)
- HMGCR and knee OA (β)
- −0.193, PSMR = 0.017
- HMGCR and hip OA (β)
- 0.067, PSMR = 0.502
- Suggested that statins' protective effect on OA may not be related to its lipid-lowering effect
Original publication
Potential Benefits of Statin Therapy in Reducing Osteoarthritis Risk: A Mendelian Randomization Study. Arthritis Care Res (Hoboken). Published 16 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →